Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 févr. 2026 09h24 HE | Source: Fortress Biotech, Inc.

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium...
23 févr. 2026 08h30 HE | Source: Fortress Biotech, Inc.

Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium...
19 déc. 2024 13h00 HE | Source: DelveInsight Business Research LLP

Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight

New York, USA, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight Rare genetic disorders affect approximately 1 in...